While obesity alone can impact renal biomarkers, such as NGAL and ECM-related glycoproteins, we selected MHO individuals as controls to minimize variability from metabolic dysfunction and focus on the effects of early T2DM. The gene discussed is LCN2; the disease is Obesity.